BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

0

531739

GENNEX

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

GENNEX LABORATORIES LTD. Share Price Update

As of the latest trading session, GENNEX LABORATORIES LTD. share price is currently at ₹ 16.4, which is down by ₹ -0.02 from its previous closing. Today, the stock has fluctuated between ₹ 16.20 and ₹ 16.99. Over the past year, GENNEX LABORATORIES LTD. has achieved a return of -18.67 %. In the last month alone, the return has been 46.86 %. Read More...

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

GENNEX LABORATORIES LTD. fundamentals


  • Market cap (Cr)

    [-]

  • P/E Ratio (TTM)

    [-]

  • Beta

    [-]

  • Book Value / share

    [-]

  • Return on equity

    [-]%

  • EPS (TTM)

    [-]

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    [-]

info icon alternate text
  • Market cap (Cr)

    373.70

  • P/E Ratio (TTM)

    26.48

  • Beta

    1.20

  • Book Value / share

    7.87

  • Return on equity

    7.90%

  • EPS (TTM)

    0.62

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    4.15

info icon alternate text

GENNEX LABORATORIES LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 25.64
Operating Expense 23.05
Net Profit 4.15
Net Profit Margin (%) 16.18
Earnings Per Share (EPS) 0.18
EBITDA 5.64
Effective Tax Rate (%) 14.43
Particulars MAR 2025 (Values in Cr)
Revenue 23.28
Operating Expense 23.82
Net Profit 1.50
Net Profit Margin (%) 6.44
Earnings Per Share (EPS) 0.07
EBITDA 2.94
Effective Tax Rate (%) 30.73
Particulars DEC 2024 (Values in Cr)
Revenue 25.28
Operating Expense 22.39
Net Profit 4.21
Net Profit Margin (%) 16.65
Earnings Per Share (EPS) 0.19
EBITDA 5.57
Effective Tax Rate (%) 15.12
Particulars SEP 2024 (Values in Cr)
Revenue 24.69
Operating Expense 21.50
Net Profit 4.16
Net Profit Margin (%) 16.84
Earnings Per Share (EPS) 0.18
EBITDA 5.52
Effective Tax Rate (%) 16.96
Particulars JUN 2024 (Values in Cr)
Revenue 21.33
Operating Expense 18.86
Net Profit 4.17
Net Profit Margin (%) 19.54
Earnings Per Share (EPS) 0.18
EBITDA 5.38
Effective Tax Rate (%) 15.24
Particulars MAR 2025 (Values in Cr)
Revenue 94.58
Operating Expense 86.58
Net Profit 14.04
Net Profit Margin (%) 14.84
Earnings Per Share (EPS) 0.62
EBITDA 19.41
Effective Tax Rate (%) 17.70
Particulars MAR 2024 (Values in Cr)
Revenue 86.71
Operating Expense 75.13
Net Profit 13.18
Net Profit Margin (%) 15.20
Earnings Per Share (EPS) 0.70
EBITDA 21.94
Effective Tax Rate (%) 20.13
Particulars MAR 2023 (Values in Cr)
Revenue 65.10
Operating Expense 62.48
Net Profit 4.56
Net Profit Margin (%) 7.00
Earnings Per Share (EPS) 0.26
EBITDA 7.98
Effective Tax Rate (%) 24.12
Particulars MAR 2022 (Values in Cr)
Revenue 61.21
Operating Expense 57.50
Net Profit 3.92
Net Profit Margin (%) 6.40
Earnings Per Share (EPS) 0.33
EBITDA 6.76
Effective Tax Rate (%) 22.98
Particulars MAR 2021 (Values in Cr)
Revenue 59.65
Operating Expense 54.74
Net Profit 4.04
Net Profit Margin (%) 6.77
Earnings Per Share (EPS) 0.32
EBITDA 6.68
Effective Tax Rate (%) 20.15
Particulars MAR 2025 (Values in Cr)
Book Value / Share 7.96
ROE % 10.15
ROCE % 12.40
Total Debt to Total Equity 0.04
EBITDA Margin 17.28
Particulars MAR 2024 (Values in Cr)
Book Value / Share 7.24
ROE % 10.51
ROCE % 13.64
Total Debt to Total Equity 0.03
EBITDA Margin 22.31
Particulars MAR 2023 (Values in Cr)
Book Value / Share 4.46
ROE % 7.91
ROCE % 10.17
Total Debt to Total Equity 0.09
EBITDA Margin 12.02
Particulars MAR 2022 (Values in Cr)
Book Value / Share 3.46
ROE % 9.35
ROCE % 11.78
Total Debt to Total Equity 0.21
EBITDA Margin 10.36
Particulars MAR 2021 (Values in Cr)
Book Value / Share 3.14
ROE % 10.67
ROCE % 13.16
Total Debt to Total Equity 0.16
EBITDA Margin 10.49
Particulars MAR 2025 (Values in Cr)
Book Value / Share 7.87
ROE % 7.90
ROCE % 10.25
Total Debt to Total Equity 0.01
EBITDA Margin 18.47
Particulars MAR 2024 (Values in Cr)
Book Value / Share 7.26
ROE % 9.45
ROCE % 12.50
Total Debt to Total Equity 0.01
EBITDA Margin 22.59
Particulars MAR 2023 (Values in Cr)
Book Value / Share 4.39
ROE % 7.41
ROCE % 10.69
Total Debt to Total Equity 0.09
EBITDA Margin 11.20
Particulars MAR 2022 (Values in Cr)
Book Value / Share 3.48
ROE % 9.35
ROCE % 11.78
Total Debt to Total Equity 0.21
EBITDA Margin 10.36
Particulars MAR 2021 (Values in Cr)
Book Value / Share 3.15
ROE % 10.67
ROCE % 13.17
Total Debt to Total Equity 0.16
EBITDA Margin 10.49
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 55.56
Total Assets 256.03
Total Liabilities 256.03
Total Equity 194.58
Share Outstanding 227447674
Price to Book Ratio 1.53
Return on Assets (%) 7.07
Return on Capital (%) 8.85
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 60.97
Total Assets 229.98
Total Liabilities 229.98
Total Equity 176.46
Share Outstanding 227447674
Price to Book Ratio 2.18
Return on Assets (%) 5.72
Return on Capital (%) 7.23
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 15.06
Total Assets 132.31
Total Liabilities 132.31
Total Equity 86.51
Share Outstanding 180192662
Price to Book Ratio 1.28
Return on Assets (%) 3.71
Return on Capital (%) 5.62
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 8.31
Total Assets 68.02
Total Liabilities 68.02
Total Equity 43.81
Share Outstanding 126503000
Price to Book Ratio 2.16
Return on Assets (%) 5.76
Return on Capital (%) 7.27
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.06
Total Assets 58.90
Total Liabilities 58.90
Total Equity 39.70
Share Outstanding 126503000
Price to Book Ratio 1.24
Return on Assets (%) 6.85
Return on Capital (%) 8.58
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 55.56
Total Assets 218.38
Total Liabilities 218.38
Total Equity 184.79
Share Outstanding 227447674
Price to Book Ratio 1.53
Return on Assets (%) 6.42
Return on Capital (%) 7.55
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 60.96
Total Assets 205.33
Total Liabilities 205.33
Total Equity 170.75
Share Outstanding 227447674
Price to Book Ratio 2.18
Return on Assets (%) 5.74
Return on Capital (%) 6.87
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 14.45
Total Assets 96.22
Total Liabilities 96.22
Total Equity 79.01
Share Outstanding 180192661
Price to Book Ratio 1.28
Return on Assets (%) 4.73
Return on Capital (%) 5.7
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 8.31
Total Assets 68.20
Total Liabilities 68.20
Total Equity 43.99
Share Outstanding 126503000
Price to Book Ratio 2.16
Return on Assets (%) 5.75
Return on Capital (%) 7.25
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.06
Total Assets 59.08
Total Liabilities 59.08
Total Equity 39.89
Share Outstanding 126503000
Price to Book Ratio 1.24
Return on Assets (%) 6.83
Return on Capital (%) 8.55
Particulars MAR 2025 (Values in Cr)
Net Income 21.39
Cash from Operations -7.57
Cash from Investing 0.82
Cash from Financing 4.56
Net change in Cash -5.40
Free Cash Flow 1.36
Particulars MAR 2024 (Values in Cr)
Net Income 16.49
Cash from Operations -46.68
Cash from Investing 18.91
Cash from Financing 73.68
Net change in Cash 45.91
Free Cash Flow -46.68
Particulars MAR 2023 (Values in Cr)
Net Income 6.37
Cash from Operations 23.67
Cash from Investing -38.32
Cash from Financing 21.03
Net change in Cash 6.38
Free Cash Flow 63.46
Particulars MAR 2022 (Values in Cr)
Net Income 5.27
Cash from Operations 13.01
Cash from Investing -2.46
Cash from Financing -1.83
Net change in Cash 7.61
Free Cash Flow 14.61
Particulars MAR 2021 (Values in Cr)
Net Income 5.06
Cash from Operations 0.09
Cash from Investing -0.02
Cash from Financing 1.61
Net change in Cash 0.15
Free Cash Flow 0.17
Particulars MAR 2025 (Values in Cr)
Net Income 17.06
Cash from Operations -9.51
Cash from Investing 2.63
Cash from Financing 1.52
Net change in Cash -5.35
Free Cash Flow -3.56
Particulars MAR 2024 (Values in Cr)
Net Income 14.86
Cash from Operations -32.33
Cash from Investing 0.92
Cash from Financing 79.01
Net change in Cash 46.51
Free Cash Flow -29.49
Particulars MAR 2023 (Values in Cr)
Net Income 6.01
Cash from Operations -14.45
Cash from Investing -0.76
Cash from Financing 21.35
Net change in Cash 6.13
Free Cash Flow -12.22
Particulars MAR 2022 (Values in Cr)
Net Income 5.27
Cash from Operations 7.74
Cash from Investing -1.26
Cash from Financing 1.86
Net change in Cash 7.24
Free Cash Flow 8.13
Particulars MAR 2021 (Values in Cr)
Net Income 5.06
Cash from Operations 0.09
Cash from Investing -0.02
Cash from Financing 1.61
Net change in Cash 0.15
Free Cash Flow 0.17
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 32.54 13.28 1.78 249.36 30.00 / 68.00
BLISS GVS PHARMA LTD 152.15 15.08 1.53 1607.46 105.05 / 190.65
CIPLA LTD 1580.75 23.68 4.09 127687.56 1310.05 / 1672.20
FERMENTA BIOTECH LIMITED 262.85 7.40 2.13 773.59 219.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 32.54 17.68 5.14 249.36 30.00 / 68.00
AMRUTAJAN HEALTH LTD 743.40 39.42 6.58 2149.22 548.05 / 829.00
ASTRAZENECA PHARMA IND LT 9338.45 110.40 30.30 23346.13 6222.35 / 10653.05
BLISS GVS PHARMA LTD 152.15 22.78 1.51 1607.46 105.05 / 190.65

GENNEX LABORATORIES LTD. shareholding pattern

Holding

Others
76.37%
Promoter Holdings
23.62%
FII
0.0%
DII
0.0%
Promoter Shares(Pledge Percentage)
17.43%
Name Shares Category
Premier Fiscal Services Private Limited 5.3038E7 (21.83%) Shareholding of Promoter and Promoter Group
Jms Mines & Minerals Private Limited 7900000.0 (3.25%) Public Shareholding
Sanjay Kumar 3726850.0 (1.53%) Public Shareholding
Rajababu Sampatrao Bandela 3427580.0 (1.41%) Public Shareholding
Vab Ventures Limited 3432170.0 (1.41%) Shareholding of Promoter and Promoter Group
Subhash Chand Bhura Trusteeof Anuj Bhura Welfare Trust 765450.0 (0.32%) Shareholding of Promoter and Promoter Group
Miraj Digvijay Shah 400000.0 (0.16%) Public Shareholding
Enforcement Directorate Raipur 62000.0 (0.03%) Public Shareholding
Prudential Investment Limited 39820.0 (0.02%) Shareholding of Promoter and Promoter Group
India Securities Brooking Private Limited 60384.0 (0.02%) Shareholding of Promoter and Promoter Group
Vinod Baid 48000.0 (0.02%) Shareholding of Promoter and Promoter Group
Vab Capital Advisors Private Limited 1500.0 (0.0%) Shareholding of Promoter and Promoter Group
Gopalakrishnan Muralidharan Tiruvarur 150.0 (0.0%) Shareholding of Promoter and Promoter Group
Arihant Baid 150.0 (0.0%) Shareholding of Promoter and Promoter Group

Transparent Pricing and 360° Services

Choose a Plan That Suits Your Goals and Needs

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : ₹2,500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% on Delivery 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Stock Picks by Research Analysts tick Experienced Dealer Support

GENNEX LABORATORIES LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
16.43 0.06 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 16.10
  • 26 Days 14.00
  • 10 Days 15.30
  • 50 Days 13.30
  • 12 Days 15.10
  • 100 Days 13.20
  • 20 Days 14.30
  • 200 Days 13.80
16.52 PIVOT

First Support

16.14

First Resistance

16.80

Second Support

15.86

Second Resistance

17.18

Third Support

15.48

Third Resistance

17.46

RSI

75.18

ADX

41.61

MACD

1.10

Williams % R

-15.66

Commodity Channel Index (CCI)

133.49

Date

2025-10-30

Week

1895245.00

Same Day

1359330.00

Month

1257073.00

1 Year

1.21

3 Year

0.65

Over 1 Month

46.86%

down

Over 1 Year

-18.67%

down

Over 3 Months

27.28%

down

Over 3 Years

39.03%

down

Over 6 Months

24.48%

down

Over 5 Years

34.64%

down

GENNEX LABORATORIES LTD. Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
14 Dec 2009 10.0 1.0 15 Dec 2009

GENNEX LABORATORIES LTD. Share Price

Gennex Laboratories Limited (formerly Prudential Pharmaceuticals Limited) was incorporated on June 25, 1985. The Company got converted into a Public Limited Company and the name was changed from Prudential Pharmaceuticals Limited to Gennex Laboratories Limited in 2007.

The Company is one of the leading manufacturers and exporters of Active pharmaceutical ingredients and Intermediates. It is engaged in manufacturing and marketing of bulk drugs and intermediates.

Gennex is among the leading Vertically Integrated' pharmaceutical companies in India and has a robust product portfolio spread over major product segments encompassing Expectorants, Muscle Relaxants, Analgesic and Anti Fungal. The company thrives on the strength of its exports to various countries viz. Germany, United Kingdom, Spain, Singapore, Canada, Switzerland, Iran, Bangladesh, Pakistan and Others. The Company's factory is situated at Andhra Pradesh, India. The company has a professionally managed team at every stage of its operations.

During the year 2005-2006, the company implemented GMP (Good Manufacturing Practices). In 2006-07, it installed Separate Air Handling System in final drug isolation area and also in drying and packing area. Also, it implemented the CGMP in manufacturing area as per ICH & WHO Guidelines. In 2007-2008, it diversified into the business of Biotech product.

The Company acquired 51% shareholding in Deccan Remedies Limited and thus became the subsidiary of the Company in 2023.

Parent organization Prudential
NSE symbol [-]
Founded 1990
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Gennex Laboratories Ltd?

Answer Field

Gennex Laboratories Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 16.43 as on Oct 31 2025 03:29 PM.

What is the Market Cap of Gennex Laboratories Ltd Share?

Answer Field

The market cap of Gennex Laboratories Ltd for NSE ₹ 0.00 & for BSE ₹ 373.70 as on Oct 31 2025 03:29 PM.

What is the 52 Week High and Low of Gennex Laboratories Ltd?

Answer Field

The 52 Week High and Low of Gennex Laboratories Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 22.50 and ₹ 10.84.

What is 1 year return for Gennex Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been -18.67%.

What is the P/E Ratio of Gennex Laboratories Ltd Share?

Answer Field

As on Oct 31 2025 03:29 PM the price-to-earnings (PE) ratio for Gennex Laboratories Ltd share is 26.48.

What is the PB ratio of Gennex Laboratories Ltd Share?

Answer Field

As on Oct 31 2025 03:29 PM, the price-to-book (PB) ratio for Gennex Laboratories Ltd share is 7.87.

How to Buy Gennex Laboratories Ltd Share?

Answer Field

You can trade in Gennex Laboratories Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Gennex Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Gennex Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Gennex Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59